The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

By sjmartinez • November 26, 2022

Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, Chan JW, Cummings AL, Daly ME, Goldman JW, Gubens MA, Harris JP, Onaitis MW, Zhu VW, Patel SP, Kelly K. The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study. JTO Clin Res Rep. 2022 Oct 29;3(12):100427. doi: 10.1016/j.jtocrr.2022.100427. PMID: 36426286; PMCID: PMC9679033.

Tags: Actionable mutations, chemotherapy, Driver mutations, General Internal Medicine, immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic driven, Publications

Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right Atrial Rupture

Makaroff KE, Hampilos K, Sayed S, Emert B, Hu X, Nsair A, Kwon M, Middlekauff H. Primary Cardiac Angiosarcoma Leading to Tamponade and Fatal Right[...]

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals

Tian J, Azhir A, Decaro M, Chau N, Hügel J, Morris M, Cheng J, Fard P, Bassett IV, Bell DS, Bernstam EV, Visweswaran S, Klann[...]

Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among Veterans with Prediabetes by Race and Ethnicity, 2010-2019

Ly DP, Washington DL, Shekelle PG, Lee ML, Moin T. Use of Evidence-Based Type 2 Diabetes Preventive Therapies and Rates of Progression to Diabetes Among[...]